The authors should have looked at our 10 March 2022 announcement regarding the work of Professor Verrills and team's preclinical study:
https://announcements.raceoncology.com/announcements/4100695
Conclusions
• Zantrene can kill kidney cancer cells at clinically relevant concentrations as a singleagent.
• Zantrene can slow the growth of kidney cancer cells at sub-cytotoxic drugconcentrations.
• Zantrene shows strong and robust synergy when used with a number of existingkidney cancer drugs, especially those that inhibit VEGFR or the mTOR pathways.
• The synergistic combinations have high clinical relevance and potential for rapidtranslation into the clinic.
Though they would need to know Zantrene is CS1
Interestingly, not all FTO inhibitors have the same effect (from the announcement):
The authors should have looked at our 10 March 2022 announcement...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
